Online inquiry

IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12609MR)

This product GTTS-WQ12609MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets F11 gene. The antibody can be applied in Thromboembolic diseases research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000128.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2160
UniProt ID P03951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12609MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2459MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 181
GTTS-WQ5220MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CB 2679d
GTTS-WQ3983MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BG9924
GTTS-WQ4835MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BT-062
GTTS-WQ15540MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ4369MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-188667
GTTS-WQ2865MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-570
GTTS-WQ10901MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MABp1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW